Suneil Kalia

Suneil Kalia, PhD, MD

Suneil Kalia, MD, PhD, FRCS(C), is a scientist at Krembil Research Institute and Assistant Professor in Neurosurgery at the University of Toronto. His research laboratory focuses on understanding molecular mechanisms of protein homeostasis in neurodegeneration and on establishing model systems to study protein function in Parkinson’s disease (PD). As a neurosurgeon his clinical focus is on the surgical management of movement disorders, particularly PD.

Dr. Kalia received his BSc at McGill University and his MD and PhD degrees from the University of Toronto. In 2006 he entered the neurosurgery residency program at University of Toronto, during which he completed a postdoctoral research fellowship at the Massachusetts General Hospital Institute for Neurodegenerative Disease at Harvard University. After obtaining his FRCS(C) in neurosurgery, he undertook subspecialty training in stereotactic and functional neurosurgery at the Toronto Western Hospital.

His team is actively working on developing novel biological therapies that are designed to slow or halt the progression of neurodegeneration in PD.
Parkinson’s disease (PD) is a disabling movement disorder that affects between 1-3% of the Canadian population over the age of 65. Poor handling and elimination of misfolded proteins has been identified as central in the molecular pathogenesis of PD. A special class of proteins within the cell called “chaperones” is responsible for refolding misfolded or damaged proteins. If the chaperone system cannot adequately deal with these misfolded proteins, they are targeted to specialized disposal systems in the cell including the ubiquitin-proteasome system and the autophagy-lysosomal system. Together these pathways are critical to maintain protein quality control within a cell. If they are dysfunctional or overwhelmed then neurodegeneration ensues.
Our current work is aimed at:
1)      Understanding how chaperone molecules fail to maintain adequate protein quality control in PD and other neurodegenerative disorders;
2)      Dissecting molecular pathways that contribute to aberrant protein disposal via the proteasome and lysosomal systems in PD; and,
3)      Developing innovative methods to target and regulate these protein quality control pathways in PD and other neurodegenerative disorders.
Our ultimate goal is to find ways to mitigate the loss of neurons in the brain to be able to slow or even halt the progression of PD and other neurodegenerative disorders.
Brain Lang. 2017 Nov 07;176:1-10
Ghahremani A, Wessel JR, Udupa K, Neagu B, Zhuang P, Saha U, Kalia SK, Hodaie M, Lozano AM, Aron AR, Chen R
J Neurosurg. 2017 Nov 10;:1-8
Basha D, Dostrovsky JO, Kalia SK, Hodaie M, Lozano AM, Hutchison WD
Parkinsons Dis. 2017;2017:5015307
Friesen EL, De Snoo ML, Rajendran L, Kalia LV, Kalia SK
World Neurosurg. 2017 Jul 31;:
King NKK, Krishna V, Sammartino F, Bari A, Reddy GD, Hodaie M, Kalia SK, Fasano A, Munhoz RP, Lozano AM, Hamani C
Annu Rev Neurosci. 2017 Jul 25;40:453-477
Lozano AM, Hutchison WD, Kalia SK
Brain Stimul. 2017 Jul 13;:
Jitkritsadakul O, Bhidayasiri R, Kalia SK, Hodaie M, Lozano AM, Fasano A
J Neurosurg. 2017 Jun 30;:1-15
Mansouri A, Taslimi S, Badhiwala JH, Witiw CD, Nassiri F, Odekerken VJJ, De Bie RMA, Kalia SK, Hodaie M, Munhoz RP, Fasano A, Lozano AM
Can J Anaesth. 2017 Feb 14;:
Yeoh TY, Manninen P, Kalia SK, Venkatraghavan L
Neurosurgery. 2016 Aug 01;63(CN_suppl_1):151
Samuel N, Kalia SK, Bernstein MA, Shamji MF


Assistant Professor University of Toronto